Workshop Overview

This workshop is organized to share the status of the 2026 fiscal year Generic Drug Science and Research Initiative and to solicit public comments. Generic drugs are copies of patented medicines and represent a core strategy for enhancing cost efficiency. The Science and Research Initiative refers to a program aimed at developing new manufacturing processes and quality verification methods.

Rationale for Timing

The 2026 fiscal year marks a period of rapid expansion in the generic market, prompting the MFDS to proactively refine the regulatory environment. An increasing number of drug classes are approaching patent expiry, raising quality and safety assurance as critical challenges. Consequently, science‑based research support has become a policy priority.

Industry Impact

Through the workshop, generic manufacturers will gain insight into the latest research directions and regulatory expectations. This can accelerate the adoption of new technologies, reduce the risk of approval delays, and translate into cost savings. Moreover, expanded collaboration opportunities between academia and industry increase the likelihood of innovative manufacturing processes emerging.

Patient and Market Expectations

Improved quality of generic drugs will enable patients to access safer and more affordable treatment options more quickly. When used as substitutes for high‑cost therapies that are difficult to reimburse, a reduction in overall healthcare expenditures is anticipated. The market is expected to respond to these policy signals with higher stock valuations and increased investment appeal for generic companies.